Meeting
2024 ASCO Annual Meeting
OPTec: A phase 2 study to evaluate outpatient (OP) step-up administration of teclistamab (Tec), a BCMA-targeting bispecific antibody, in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
Authors
Robert M. Rifkin
Sarah Cannon Research Institute, Rocky Mountain Cancer Centers, Denver, CO
Robert M. Rifkin , Henning Helmut Schade , Gary Simmons , Christopher A. Yasenchak , Jessica Fowler , Thomas S. Lin , Brian Thomson , Weiming Xu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT05972135
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 7528)
DOI
10.1200/JCO.2024.42.16_suppl.7528
Abstract #
7528
Poster Bd #
165
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM).
First Author: Doris K. Hansen
Poster
2023 ASCO Annual Meeting
Durability of responses with biweekly dosing of teclistamab in patients with relapsed/refractory multiple myeloma achieving a clinical response in the majesTEC-1 study.
First Author: Saad Zafar Usmani
Poster
2023 ASCO Annual Meeting
Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies.
First Author: Ross Firestone
Poster
2022 ASCO Annual Meeting
Health-related quality of life in patients with relapsed/refractory multiple myeloma (RRMM) treated with teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody: Patient-reported outcomes in MajesTEC-1.
First Author: Thomas G. Martin